Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALTHF trial

Author:

Cobo Marcos Marta12,de la Espriella Rafael3,Comín‐Colet Josep24,Zegrí‐Reiriz Isabel5,Rubio Gracia Jorge6,Morales‐Rull Jose Luis7,Llàcer Pau89,Díez‐Villanueva Pablo10,Jiménez‐Marrero Santiago24,de Juan Bagudá Javier21112,Ortiz Cortés Carolina13,Restrepo‐Córdoba Maria Alejandra14,Goirigolzarri‐Artaza Josebe14,García‐Pinilla Jose Manuel15,Barrios Elvira16,del Prado Díaz Susana217,Montero Hernández Esther18,Sanchez‐Marteles Marta6,Núñez Julio23

Affiliation:

1. Department of Cardiology Hospital Universitario Puerta de Hierro Madrid Spain

2. Centro de Investigación Biomédica en Red (CIBER Cardiovascular) Madrid Spain

3. Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA) University of Valencia Valencia Spain

4. Department of Cardiology Hospital Universitario de Bellvitge, IDIBELL Barcelona Spain

5. Department of Cardiology Hospital de la Santa Creu i Sant Pau Barcelona Spain

6. Department of Internal Medicine Hospital Universitario Lozano Blesa, University of Zaragoza, Aragon Health Research Institute (IIS Aragon) Zaragoza Spain

7. Department of Internal Medicine Hospital Universitario Arnau de Vilanova. Heart Failure Unit, Lleida Health Region. Institut de Recerca Biomèdica de Lleida (IRBLleida) Lleida Spain

8. Department of Internal Medicine Hospital Universitario Ramón y Cajal, IRYCIS Madrid Spain

9. Department of Medicine and Medical Specialties, Facultad de Medicina y Ciencias de la Salud Universidad de Alcalá Madrid Spain

10. Department of Cardiology Hospital Universitario de la Princesa Madrid Spain

11. Department of Cardiology University Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12) Madrid Spain

12. Department of Medicine, Faculty of Biomedical and Health Science Universidad Europea de Madrid Madrid Spain

13. Department of Cardiology Hospital Universitario San Pedro de Alcántara Cáceres Spain

14. Department of Cardiology Hospital Universitario Clínico San Carlos Madrid Spain

15. Department of Cardiology Hospital Universitario Virgen de la Victoria, Málaga, Spain, Instituto de Investigación Biomédica‐Plataforma BIONAND, Málaga Ciber‐Cardiovascular, Insitituto de Salud Carlos III, Departamento de Medicina y Dermatología, Universidad de Málaga, Málaga, Spain

16. Department of Cardiology Hospital Universitario Rey Juan Carlos Móstoles Madrid Spain

17. Department of Cardiology Hospital Universitario Ramón y Cajal Madrid Spain

18. Department of Internal Medicine Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain

Abstract

AimsCombination of hypertonic saline solution (HSS) with intravenous loop diuretics has been suggested to improve diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this approach in the ambulatory setting remain unexplored.Methods and resultsIn this multicentre, double‐blind, randomized study, we allocated ambulatory patients with worsening heart failure (WHF) to a 1‐h infusion of intravenous furosemide (ivFurosemide)‐HSS versus ivFurosemide. The primary endpoint was the volume of diuresis at 3 h. Secondary endpoints included 3‐h natriuresis and weight variation, 7‐day congestion data, kidney function and electrolytes, and 30‐day clinical events. Overall, 167 participants (median age: 81 years, 30.5% female) were randomized across 13 sites between December 2020 and March 2023. There were no differences in 3‐h diuresis between treatments (ivFurosemide‐HSS: 1099 ml vs. ivFurosemide: 1103 ml, p = 0.963), 3‐h natriuresis (∆ +2.642 mEq/L, p = 0.559), or 3‐h weight (∆ +0.012 kg, p = 0.920). Patients in the ivFurosemide‐HSS arm experienced significant weight decrease at 7 days (Δ −0.586 kg, p = 0.048). There were no between‐treatment differences in clinical congestion score, biomarkers, inferior vena cava diameter, or the presence of lung ultrasound B‐lines. At 30 days, 26.5% of the patients in the ivFurosemide‐HSS group versus 33.3% in the ivFurosemide group experienced WHF (hazard ratio 0.76, p = 0.330). The incidence of death from any cause or HF hospitalization was 6% of patients in the ivFurosemide‐HSS group and 8.3% of patients in the ivFurosemide group (hazard ratio 0.69, p = 0.521). The incidence of worsening kidney function or metabolic derangements was not significantly different in the two arms.ConclusionsA single infusion of ivFurosemide‐HSS did not improve 3‐h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.

Funder

Instituto de Salud Carlos III

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3